Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes (January 2021)

Umesh Dashora, consultant (diabetes), honorary reader, deputy sub-dean and meeting secretary ABCD^A ⇑,
Robert Gregory, consultant physician^B,
Peter Winocour, consultant physician and clinical director^C,
Ketan Dhatariya, consultant physician and honorary professor^D,
Susannah Rowles, consultant diabetologist^E,
Andrew Macklin, consultant diabetologist^F,
Gerry Rayman, consultant diabetologist, honorary professor and clinical lead for diabetes GIRFT^G,
Dinesh Nagi, honorary consultant in diabetes and endocrinology, and Ex Officio (Chair) ABCD^H,
Katie Whitehead, practice nurse^I,
Hannah Beba, senior clinical pharmacist in diabetes and endocrinology, and co-chair diabetes and endocrinology committee UKCPA^J,
Parijat De, consultant physician in diabetes and endocrinology^K,
Dipesh C Patel, consultant physician in diabetes and endocrinology, and honorary associate professor^L,
on behalf of the ABCD executive committee and Diabetes UK

Address for correspondence: Dr Umesh Dashora, Diabetes and Endocrinology, Conquest Hospital, East Sussex Healthcare NHS Trust, The Ridge, St Leonards-on-Sea, East Sussex TN37 7RD, UK. Email: u.dashora{at}nhs.net Twitter: @dashorau

Article usage